A RANDOMISED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTRE PROOF OF CONCEPT STUDY TO ASSESS THE SAFETY AND EFFICACY OF TWO DOSES OF VAD044 IN PATIENTS WITH HEREDITARY HAEMORRHAGIC TELANGIECTASIA (HHT)

Registry ID

VAD044C002

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

VADERIS THERAPEUTICS AG

Last update

2022-04-14

Conditions

• HEREDITARY HAEMORRHAGIC TELANGIECTASIA

Related clinical trials

• A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2-PART STUDY OF THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE DOSE ALN-6400 IN ADULT HEALTHY VOLUNTEERS AND MULTIPLE DOSE ALN-6400 IN ADULT PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
• DOXYCYCLINE CROSSOVER TRIAL FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

View on source registry